

# Simona Leoni

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1833218/simona-leoni-publications-by-citations.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

20  
papers

1,199  
citations

13  
h-index

23  
g-index

23  
ext. papers

1,486  
ext. citations

4.4  
avg, IF

4.06  
L-index

#	Paper	IF	Citations
20	Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. <i>Hepatology</i> , <b>2005</b> , 42, 27-34	11.2	356
19	Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. <i>World Journal of Gastroenterology</i> , <b>2018</b> , 24, 3361-3373	5.6	203
18	The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria. <i>American Journal of Gastroenterology</i> , <b>2010</b> , 105, 599-609	0.7	151
17	Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter retrospective study of 1,006 nodules. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 485-492	13.4	116
16	Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound. <i>Liver International</i> , <b>2013</b> , 33, 771-9	7.9	74
15	Characterization of liver lesions by real-time contrast-enhanced ultrasonography. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2007</b> , 19, 3-14	2.2	58
14	The role of ultrasound elastographic techniques in chronic liver disease: current status and future perspectives. <i>European Journal of Radiology</i> , <b>2014</b> , 83, 450-5	4.7	46
13	Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: experience of the Bologna Liver Oncology Group. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 549-55	3.3	43
12	A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system. <i>Liver Transplantation</i> , <b>2007</b> , 13, 857-66	4.5	38
11	History of Nonalcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	30
10	Treatment of hepatocellular carcinoma in Child-Pugh B patients. <i>Digestive and Liver Disease</i> , <b>2013</b> , 45, 852-8	3.3	25
9	Long-term durable response to lenalidomide in a patient with hepatic epithelioid hemangioendothelioma. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 7049-54	5.6	18
8	Treatment of Combined Hepatocellular and Cholangiocarcinoma. <i>Cancers</i> , <b>2020</b> , 12,	6.6	17
7	Cost analysis of recall strategies for non-invasive diagnosis of small hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , <b>2010</b> , 42, 729-34	3.3	9
6	Determination of Effective Albumin in Patients With Decompensated Cirrhosis: Clinical and Prognostic Implications. <i>Hepatology</i> , <b>2021</b> , 74, 2058-2073	11.2	8
5	Contrast-enhanced ultrasound in liver cancer. <i>Hepatic Oncology</i> , <b>2015</b> , 2, 51-62	4	3
4	Assessment of long-term prognosis at detection of early hepatocellular carcinoma remains unsolved. <i>Journal of Hepatology</i> , <b>2014</b> , 61, 1438	13.4	

- 3 Direct antiviral agents for HCV infection and hepatocellular carcinoma: facts and FADs.. *Translational Cancer Research*, **2019**, 8, S223-S232 0.3
- 2 Clinical predictors of response to sorafenib in patients with hepatocellular carcinoma.. *Journal of Clinical Oncology*, **2013**, 31, e15149-e15149 2.2
- 1 Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience. *Targeted Oncology*, **2021**, 16, 653-661 5